Fujian Cancer Hospital Trials

Fujian Cancer Hospital	Welcome, Profile Billing Logout

140 Trials

Active Trials

12 »

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Guo, Ye

MRG003-010, NCT05751512: A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Not yet recruiting

180

RoW

MRG003, Cetuximab injection, Methotrexate Injection

Shanghai Miracogen Inc.

Squamous Cell Carcinoma of the Head and Neck

08/25

12/25

NCT05254665: A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors

Not yet recruiting

110

RoW

Docetaxel Polymeric Micelles for Injection

Jiangsu Simcere Pharmaceutical Co., Ltd.

Advanced Solid Tumors

12/22

03/24

NCT04868162: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recruiting

120

RoW

MRG003

Shanghai Miracogen Inc.

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

01/23

09/23

NCT05044897: A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Recruiting

RoW

SI-B001

Sichuan Baili Pharmaceutical Co., Ltd.

Head and Neck Squamous Cell Carcinoma

06/25

NCT05054439: A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Recruiting

RoW

SI-B001, Paclitaxel

Sichuan Baili Pharmaceutical Co., Ltd.

Head and Neck Squamous Cell Carcinoma

06/25

NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Recruiting

200

RoW

ICP-192

Beijing InnoCare Pharma Tech Co., Ltd.

Advanced Solid Tumor

12/23

06/24

HLX10HLX07-001, NCT04297995: Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Active, not recruiting

131

RoW

HLX10, HLX07, HLX07 placebo, Cisplatin/Carboplatin, 5-FU

Shanghai Henlius Biotech

Head and Neck Squamous Cell Carcinoma

05/24

06/25

NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Recruiting

RoW

LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection

Lyvgen Biopharma Holdings Limited

Head and Neck Squamous Cell Carcinoma

10/27

NCT06194656: Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Recruiting

RoW

HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclonal antibodies-Dose D, Placebo, Cetuximab injection

Shanghai Institute Of Biological Products

Head and Neck Squamous Cell Carcinoma

07/26

NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting

238

RoW

MRG003, Capecitabine tablets, Docetaxel injection

Shanghai Miracogen Inc.

Recurrent or Metastatic Nasopharyngeal Carcinoma

10/24

02/25

HG146CN201, NCT06781567: Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

Recruiting

140

RoW

HG146, HG146 Capsule

HitGen Inc.

Adenoid Cystic Carcinoma, Head and Neck Cancer

12/28

06/29

NCT06007729: ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting

170

RoW

HS-20093

Hansoh BioMedical R&D Company

Head and Neck Squamous Cell Carcinoma

12/25

12/27

NCT04856631: A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Recruiting

1/2

RoW

Toripalimab Injection, Cetuximab Solution for infusion

Shanghai Junshi Bioscience Co., Ltd.

Head and Neck Squamous Cell Cancer

11/22

11/23

PM8002-A001, NCT05918445: PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting

1/2

380

RoW

PM8002

Biotheus Inc.

Malignant Neoplasm

11/25

NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Recruiting

1/2

RoW

T3011 high dose, T3011 middle dose, T3011 low dose

Shanghai Pharmaceuticals Holding Co., Ltd

Advanced Solid Tumors

12/25

05/26

NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Recruiting

1/2

RoW

APG-115, Toripalimab

Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.

Liposarcoma, Advanced Solid Tumor

04/26

01/27

NCT05867771: A Study of PM1022 in Patients With Advanced Tumors

Recruiting

1/2

200

RoW

PM1022

Biotheus Inc.

Advanced Tumors

04/24

04/25

NCT05668858: Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting

1/2

RoW

SI-B001, SI-B003

Sichuan Baili Pharmaceutical Co., Ltd.

Squamous Cell Carcinoma of Head and Neck

06/25

12/25

NCT05839106: Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors

Recruiting

1/2

200

RoW

PM1032 injection, PM1032

Biotheus Inc.

Advanced Tumor

04/25

12/25

NCT05862831: Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors

Recruiting

1/2

285

RoW

PM1003 Injection

Biotheus Inc.

Advanced Solid Tumors

09/25

11/25

Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Active, not recruiting

1/2

374

Europe, Canada, Japan, US, RoW

Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil

Takeda, Takeda Development Center Americas, Inc. (TDC Americas)

Solid Neoplasms

01/26

NCT03869632: First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors

Recruiting

RoW

YL-13027

Shanghai YingLi Pharmaceutical Co. Ltd.

Advanced Solid Tumors

04/21

06/22

NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Recruiting

108

RoW

MRG001

Shanghai Miracogen Inc.

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

10/22

10/23

NCT06292858: Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors

Recruiting

RoW

IMB071703 injection

Beijng Immunoah Pharma Tech Co., Ltd.

Recurrent or Metastatic, Advanced Solid Tumors

04/25

08/25

NCT05552807: SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting

120

RoW

SCT-I10A, SCT200, paclitaxel, docetaxel

Sinocelltech Ltd.

Head and Neck Squamous Carcinoma

09/23

NCT06225856: An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Recruiting

RoW

YY201

Shanghai Yuyao Biotech Co., Ltd.

Advanced Solid Tumor, Hematological Malignancy

12/26

NCT05607563: A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours

Recruiting

RoW

PM1009 injection, PM1009

Biotheus Inc.

Advanced Tumor

11/23

12/23

NCT04472858: A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Recruiting

RoW

Donafenib, CS1001

Suzhou Zelgen Biopharmaceuticals Co.,Ltd, CStone Pharmaceuticals

Advanced Solid Tumor

12/23

BL-B01D1-101, NCT05194982: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Recruiting

RoW

BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.

Locally Advanced or Metastatic Solid Tumor

06/25

12/25

CS5001-101, NCT05279300: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Sep 2024 - Sep 2024 : Data for adv solid tumors

Recruiting

156

US, RoW

CS5001

CStone Pharmaceuticals

Advanced Solid Tumor, Advanced Lymphoma

03/26

06/26

NCT05429008: A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm

Recruiting

RoW

HMPL-A83 injection, HMPL-A83

Hutchmed

Advanced Tumors

06/25

09/25

NCT06304571: A Study of HC006 in Subjects With Advanced Solid Tumors

Recruiting

RoW

HC006

HC Biopharma Inc.

Advanced Solid Tumor

03/26

07/26

NCT04450732 / ACTRN12620000592943: Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Recruiting

US, RoW

GQ1001

GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd

HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor

03/24

05/24

NCT04659369: Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC

Terminated

RoW

CMAB819, Nivolumab, Opdivo

Taizhou Mabtech Pharmaceutical Co.,Ltd

Squamous Cell Carcinoma of the Head and Neck

10/23

NCT06469008: A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting

RoW

BL-B16D1

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Head and Neck Squamous Cell Carcinomas, Solid Tumor

07/26

NCT05490043: A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Recruiting

RoW

ATG-101

Antengene (Hangzhou) Biologics Co., Ltd.

Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma

08/24

12/24

ADRX-0706-001, NCT06036121: A Study of ADRX-0706 in Select Advanced Solid Tumors

Recruiting

144

US, RoW

ADRX-0706

Adcentrx Therapeutics

Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer

09/25

12/26

NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting

141

Europe, Canada, Japan, US, RoW

GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227

GlaxoSmithKline

Neoplasms

09/28

Zhuang, Wu

ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer

Not yet recruiting

738

RoW

TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Extensive Small Cell Lung Cancer

12/22

NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Recruiting

404

RoW

PM8002, Paclitaxel, Topotecan

Biotheus Inc.

SCLC

01/27

12/28

NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Recruiting

200

RoW

TQ-B3101

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Malignant Tumor

03/21

09/21

STAMP, NCT04933175: Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

Not yet recruiting

RoW

Fluzoparil, Anlotinib

Liu Zhenhua

Extensive Stage Small Cell Lung Cancer

06/22

06/23

NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

Recruiting

RoW

HLX07+HLX10+ Cisplatin+5-FU, HLX07

Shanghai Henlius Biotech

ESCC or Esophageal Adenosquamous Carcinoma

06/24

08/25

NCT04824079: Keynatinib in Treated Patients With NSCLC and Brain Metastases

Recruiting

RoW

Keynatinib, TL007

Medolution Ltd.

Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases

04/25

07/25

NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting

121

RoW

BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, SI-B003

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

11/25

SKB264-II-04, NCT05816252: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer () (MK-2870-003)

Recruiting

498

Europe, RoW

SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT), Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate

Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Non-small Cell Lung Cancer

12/25

10/26

NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting

1/2

133

RoW

KC1036

Beijing Konruns Pharmaceutical Co., Ltd.

Digestive System Tumors

10/25

12/25

NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Recruiting

RoW

JMT101, Afatinib or Osimertinib

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

12/21

06/22

GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting

150

RoW

GQ1005

GeneQuantum Healthcare (Suzhou) Co., Ltd.

HER2 Expressing or Mutated Advanced Malignant Solid Tumors

12/24

07/25

NCT03917043: APG-2449 in Patients With Advanced Solid Tumors

Recruiting

165

RoW

APG-2449, APG-2449 Capsule

Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.

Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma

12/27

01/28

NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Not yet recruiting

N/A

RoW

Osimertinib

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations

06/23

08/23

Lin, Rongbo

FNF-014, NCT03788226: A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

Recruiting

600

RoW

POF, CAPOX/SOX/FOLFOX

Fujian Cancer Hospital

Gastric Cancer Stage III

12/21

12/23

NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting

560

RoW

Irinotecan Hydrochloride Injection, HX008, Placebo

Taizhou Hanzhong biomedical co. LTD

Stomach Cancer

08/23

HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting

920

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

ANCHOR, NCT04854668: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, not recruiting

748

RoW

Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin, Capecitabine

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Metastatic Colorectal Cancer

12/24

12/25

NCT04734249: Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Not yet recruiting

Surufatinib(HMPL-012), Chemotherapy(mFOLFOX6/FOLFIRI,FOLFOXIRI)

Fujian Cancer Hospital

Advanced Colorectal Cancer

03/21

12/23

NCT05839470: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Recruiting

RoW

cadonilimab, irinotecan, Oxaliplatin, leucovorin or levoleucovorin, 5-FU

Fujian Cancer Hospital

Colorectal Cancer

03/24

03/25

TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Not yet recruiting

168

RoW

TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Chemotherapy

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Gastroesophageal Adenocarcinoma

09/26

09/27

NCT06166836: a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Recruiting

1/2

140

RoW

D1553, IN10018（Ifebemtinib）, BI 853520

InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd

Solid Tumor

12/25

12/26

NCT06825494: Clinical Studies for the Treatment of Advanced Solid Tumors

Recruiting

1/2

134

RoW

LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine, LM-108 injection 10mg/kg +penpulimab, LM-108 injection 600mg + penpulimab

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Advanced Solid Tumor

03/26

09/26

NCT04718402: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Terminated

RoW

Mitoxantrone Hydrochloride Liposome, intravenous injection

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Advanced Gastric Carcinoma

05/22

GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting

150

RoW

GQ1005

GeneQuantum Healthcare (Suzhou) Co., Ltd.

HER2 Expressing or Mutated Advanced Malignant Solid Tumors

12/24

07/25

NCT05502393: A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Recruiting

118

RoW

JS107, Toripalimab

Shanghai Junshi Bioscience Co., Ltd.

Advanced Solid Tumors

07/24

12/24

NCT05461768: A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Recruiting

RoW

BL-M07D1

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Breast Cancer, Locally Advanced or Metastatic Solid Tumor

06/25

12/25

NCT06832982: Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

Recruiting

RoW

FS-8002 injection

Shanghai Pushi Medical Science Co. Ltd

Advanced Solid Tumors

09/25

09/26

AWT020-001-I, NCT06839105: A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Not yet recruiting

214

RoW

Taxol, Cisplatin or Carboplatin, Pemetrexed, Oxaliplatin, Capecitabine, Bevacizumab, Renvastinib, AWT020

Shanghai Junshi Bioscience Co., Ltd.

Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

04/28

NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Recruiting

RoW

TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Colorectal Cancer

03/25

07/25

Chen, Yu

NCT04766307: A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

Recruiting

1100

RoW

Interleukin-2, IL-2

Beijing Chest Hospital

Tuberculosis, Pulmonary

12/21

TB-TRUST, NCT03867136: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

Completed

354

RoW

PZA sensitivity guided ultra-short all Oral Regimen, Standardized Shorter Regimen

Huashan Hospital

Multidrug Resistant Tuberculosis

08/24

NCT06041425: The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE

Completed

RoW

Oxycodone, preemptive analgesia, Sufentanil

The First Affiliated Hospital with Nanjing Medical University

Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Pain, Inflammation

12/23

ERASE, NCT06093191: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Recruiting

364

RoW

Tobramycin Inhalant Product, Inhaled antibiotics, Ciprofloxacin 750 MG, Oral antibiotics, Oral ciprofloxacin placebo, Natural saline inhalation, Inhaled saline

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult, Pseudomonas Aeruginosa Infection

10/25

12/25

MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma

06/22

09/22

NCT05114603: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Recruiting

RoW

HLX208

Shanghai Henlius Biotech

Advanced Melanoma

08/23

08/24

NCT05823246: Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

Recruiting

RoW

QLF31907

Qilu Pharmaceutical Co., Ltd.

Melanoma, Urothelial Carcinoma

10/23

07/24

NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors

Recruiting

115

RoW

VC004

Jiangsu vcare pharmaceutical technology co., LTD

Locally Advanced Solid Tumor, Metastatic Solid Tumor

01/24

06/24

NCT05664139: Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Not yet recruiting

Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel

Fujian Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd., SunWay Biotech Co., LTD.

Malignant Melanoma, Liver Metastases

12/24

12/25

NCT06609369: Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse

Recruiting

114

Experimental health intervention, Varenicline

Yale University, National Institute on Drug Abuse (NIDA)

Tobacco Use, Tobacco Cessation, Insomnia

06/29

NCT06081920: A Study of IBI363 in Subjects With Advanced Melanoma

Recruiting

120

RoW

IBI363

Innovent Biologics (Suzhou) Co. Ltd.

Melanoma

06/25

07/26

NCT04135456: The Optimal Dose of Mannitol for Intraoperative Brain Relaxation During the Operation of Aneurysmal Subarachnoid Hemorrhage

Active, not recruiting

1/2

RoW

Mannitol

Beijing Tiantan Hospital

Aneurysmal Subarachnoid Hemorrhage

11/23

01/24

NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Terminated

1/2

RoW

TJ1133 Injection

TJ Biopharma Co., Ltd.

Advanced Solid Tumor

02/23

PM8002-A001, NCT05918445: PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting

1/2

380

RoW

PM8002

Biotheus Inc.

Malignant Neoplasm

11/25

NCT06214156: A Clinical Study of T3011 in Subjects With Advanced Melanoma

Recruiting

1/2

RoW

T3011

Shanghai Pharmaceuticals Holding Co., Ltd

Advanced Melanoma

09/25

NCT05989958: The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure

Recruiting

1/2

RoW

HepaCure, DPMAS and LPE

Hexaell Biotech Co., Ltd.

Acute on Chronic Hepatic Failure, Liver Failure, Hepatitis

09/26

NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting

1/2

RoW

SPH4336, Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Advanced Solid Tumors

05/25

12/25

KY-0118-ZJKY, NCT06175780: Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting

189

RoW

KY-0118

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Neoplasms, Neoplasms by Histologic Type

12/25

NCT04773951: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Recruiting

156

RoW

JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection

Shanghai Junshi Bioscience Co., Ltd.

Melanoma, Renal Carcinoma, Urothelial Carcinoma

02/24

08/24

NCT04936178: A Study of NB003 in Patients with Advanced Malignancies

Recruiting

258

Europe, US, RoW

NB003 tablets

Ningbo Newbay Technology Development Co., Ltd

Advanced Solid Tumor

07/25

12/25

ADRX-0706-001, NCT06036121: A Study of ADRX-0706 in Select Advanced Solid Tumors

Recruiting

144

US, RoW

ADRX-0706

Adcentrx Therapeutics

Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer

09/25

12/26

DILI-P, NCT02961413: A Prospective Cohort Study on Drug-induced Liver Injury in China（）

Recruiting

N/A

10000

RoW

Drug Induced Liver Disease Study Group

Drug-induced Liver Injury

12/30

TB-TRUSTplus, NCT04717908: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

Completed

N/A

RoW

Bedaquiline, BDQ, Pyrazinamide, PZA, Linezolid, LZD, Cycloserine, Cs, Clofazimine, CFZ

Huashan Hospital

Multidrug Resistant Tuberculosis

06/24

NCT04968028: Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament

Recruiting

N/A

164

RoW

ACAF, Anterior Controllable Antedisplacement and Fusion, Laminoplasty

Shanghai Changzheng Hospital, Changhai Hospital, Shanghai 6th People's Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Tongji Hospital, Peking University Shenzhen Hospital, The Second Affiliated Hospital of Harbin Medical University, Xuanwu Hospital, Beijing, Jining Medical University, The Affiliated Hospital of Qingdao University, Shanxi Bethune Hospital, Tang-Du Hospital

Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy

07/25

12/26

rTMS, NCT06145932: Repetitive Transcranial Magnetic Stimulation Therapy in Essential Tremor

Recruiting

N/A

RoW

real rTMS, sham rTMS

Second Affiliated Hospital of Soochow University

Essential Tremor

10/26

12/26

GES-aSAH, NCT06346015: Gamma Entrainment Stimulation for Cognitive Dysfunction After aSAH

Not yet recruiting

N/A

Gamma Entrainment Stimulation, Audio-assistied therapy

Beijing Tiantan Hospital, Shanghai Joyingmed Sensory Stimulation Lab

Subarachnoid Hemorrhage, Aneurysmal, Cognitive Dysfunction

03/25

NCT06356506: A Study on Factors of Biochemical Response in Autoimmune Hepatitis

Not yet recruiting

N/A

630

RoW

Beijing Friendship Hospital

Autoimmune Hepatitis

05/34

NCT06760273: Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

Recruiting

N/A

364

RoW

No Intervention: Observational Cohort

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult

12/27

OHAVM, NCT04136860: Long-term Outcomes After Different Management Strategies for High-level Cerebral Arteriovenous Malformation

Recruiting

N/A

1000

RoW

Beijing Tiantan Hospital, Peking University International Hospital

Arteriovenous Malformation of Brain

11/24

12/24

NCT04662918: Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

Recruiting

N/A

3000

Europe, US, RoW

Xingshun Qi

GastroIntestinal Bleeding

12/24

NCT05885828: The PRECISION-T2D Study: Precision Nutrition Study for Type 2 Diabetes

Recruiting

N/A

200

RoW

White bread, Breakfast A, Whole wheat bread, Breakfast B, Plant-based diet, Conventional diabetic diet, Follow-up visit every 1-2 years

Westlake University, Hangzhou Third People's Hospital

Type 2 Diabetes

12/24

12/33

NCT05720299: A Clinical Study to Evaluate the Effects of Akkermansia Muciniphila and Berberine on Prediabetes Among Obese Subjects.

Recruiting

N/A

RoW

Akkermansia muciniphila, Berberine, AKK Placebo, Berberine Placebo

Yu Chen

Prediabetes

02/26

RADAR, NCT06902415: Application of QDSA Platform in Cerebrovascular Diseases

Recruiting

N/A

1000

RoW

QDSA (Quantitative Digital Subtraction Angiography)

Beijing Tiantan Hospital

Cerebrovascular Disease

02/30

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Guo, Ye

MRG003-010, NCT05751512: A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Not yet recruiting

180

RoW

MRG003, Cetuximab injection, Methotrexate Injection

Shanghai Miracogen Inc.

Squamous Cell Carcinoma of the Head and Neck

08/25

12/25

NCT05254665: A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors

Not yet recruiting

110

RoW

Docetaxel Polymeric Micelles for Injection

Jiangsu Simcere Pharmaceutical Co., Ltd.

Advanced Solid Tumors

12/22

03/24

NCT04868162: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recruiting

120

RoW

MRG003

Shanghai Miracogen Inc.

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

01/23

09/23

NCT05044897: A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Recruiting

RoW

SI-B001

Sichuan Baili Pharmaceutical Co., Ltd.

Head and Neck Squamous Cell Carcinoma

06/25

NCT05054439: A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Recruiting

RoW

SI-B001, Paclitaxel

Sichuan Baili Pharmaceutical Co., Ltd.

Head and Neck Squamous Cell Carcinoma

06/25

NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Recruiting

200

RoW

ICP-192

Beijing InnoCare Pharma Tech Co., Ltd.

Advanced Solid Tumor

12/23

06/24

HLX10HLX07-001, NCT04297995: Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Active, not recruiting

131

RoW

HLX10, HLX07, HLX07 placebo, Cisplatin/Carboplatin, 5-FU

Shanghai Henlius Biotech

Head and Neck Squamous Cell Carcinoma

05/24

06/25

NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Recruiting

RoW

LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection

Lyvgen Biopharma Holdings Limited

Head and Neck Squamous Cell Carcinoma

10/27

NCT06194656: Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Recruiting

RoW

HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclonal antibodies-Dose D, Placebo, Cetuximab injection

Shanghai Institute Of Biological Products

Head and Neck Squamous Cell Carcinoma

07/26

NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting

238

RoW

MRG003, Capecitabine tablets, Docetaxel injection

Shanghai Miracogen Inc.

Recurrent or Metastatic Nasopharyngeal Carcinoma

10/24

02/25

HG146CN201, NCT06781567: Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

Recruiting

140

RoW

HG146, HG146 Capsule

HitGen Inc.

Adenoid Cystic Carcinoma, Head and Neck Cancer

12/28

06/29

NCT06007729: ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting

170

RoW

HS-20093

Hansoh BioMedical R&D Company

Head and Neck Squamous Cell Carcinoma

12/25

12/27

NCT04856631: A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Recruiting

1/2

RoW

Toripalimab Injection, Cetuximab Solution for infusion

Shanghai Junshi Bioscience Co., Ltd.

Head and Neck Squamous Cell Cancer

11/22

11/23

PM8002-A001, NCT05918445: PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting

1/2

380

RoW

PM8002

Biotheus Inc.

Malignant Neoplasm

11/25

NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Recruiting

1/2

RoW

T3011 high dose, T3011 middle dose, T3011 low dose

Shanghai Pharmaceuticals Holding Co., Ltd

Advanced Solid Tumors

12/25

05/26

NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Recruiting

1/2

RoW

APG-115, Toripalimab

Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.

Liposarcoma, Advanced Solid Tumor

04/26

01/27

NCT05867771: A Study of PM1022 in Patients With Advanced Tumors

Recruiting

1/2

200

RoW

PM1022

Biotheus Inc.

Advanced Tumors

04/24

04/25

NCT05668858: Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting

1/2

RoW

SI-B001, SI-B003

Sichuan Baili Pharmaceutical Co., Ltd.

Squamous Cell Carcinoma of Head and Neck

06/25

12/25

NCT05839106: Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors

Recruiting

1/2

200

RoW

PM1032 injection, PM1032

Biotheus Inc.

Advanced Tumor

04/25

12/25

NCT05862831: Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors

Recruiting

1/2

285

RoW

PM1003 Injection

Biotheus Inc.

Advanced Solid Tumors

09/25

11/25

Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Active, not recruiting

1/2

374

Europe, Canada, Japan, US, RoW

Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil

Takeda, Takeda Development Center Americas, Inc. (TDC Americas)

Solid Neoplasms

01/26

NCT03869632: First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors

Recruiting

RoW

YL-13027

Shanghai YingLi Pharmaceutical Co. Ltd.

Advanced Solid Tumors

04/21

06/22

NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Recruiting

108

RoW

MRG001

Shanghai Miracogen Inc.

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

10/22

10/23

NCT06292858: Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors

Recruiting

RoW

IMB071703 injection

Beijng Immunoah Pharma Tech Co., Ltd.

Recurrent or Metastatic, Advanced Solid Tumors

04/25

08/25

NCT05552807: SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting

120

RoW

SCT-I10A, SCT200, paclitaxel, docetaxel

Sinocelltech Ltd.

Head and Neck Squamous Carcinoma

09/23

NCT06225856: An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Recruiting

RoW

YY201

Shanghai Yuyao Biotech Co., Ltd.

Advanced Solid Tumor, Hematological Malignancy

12/26

NCT05607563: A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours

Recruiting

RoW

PM1009 injection, PM1009

Biotheus Inc.

Advanced Tumor

11/23

12/23

NCT04472858: A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Recruiting

RoW

Donafenib, CS1001

Suzhou Zelgen Biopharmaceuticals Co.,Ltd, CStone Pharmaceuticals

Advanced Solid Tumor

12/23

BL-B01D1-101, NCT05194982: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Recruiting

RoW

BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.

Locally Advanced or Metastatic Solid Tumor

06/25

12/25

CS5001-101, NCT05279300: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Sep 2024 - Sep 2024 : Data for adv solid tumors

Recruiting

156

US, RoW

CS5001

CStone Pharmaceuticals

Advanced Solid Tumor, Advanced Lymphoma

03/26

06/26

NCT05429008: A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm

Recruiting

RoW

HMPL-A83 injection, HMPL-A83

Hutchmed

Advanced Tumors

06/25

09/25

NCT06304571: A Study of HC006 in Subjects With Advanced Solid Tumors

Recruiting

RoW

HC006

HC Biopharma Inc.

Advanced Solid Tumor

03/26

07/26

NCT04450732 / ACTRN12620000592943: Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Recruiting

US, RoW

GQ1001

GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd

HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor

03/24

05/24

NCT04659369: Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC

Terminated

RoW

CMAB819, Nivolumab, Opdivo

Taizhou Mabtech Pharmaceutical Co.,Ltd

Squamous Cell Carcinoma of the Head and Neck

10/23

NCT06469008: A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting

RoW

BL-B16D1

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Head and Neck Squamous Cell Carcinomas, Solid Tumor

07/26

NCT05490043: A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Recruiting

RoW

ATG-101

Antengene (Hangzhou) Biologics Co., Ltd.

Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma

08/24

12/24

ADRX-0706-001, NCT06036121: A Study of ADRX-0706 in Select Advanced Solid Tumors

Recruiting

144

US, RoW

ADRX-0706

Adcentrx Therapeutics

Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer

09/25

12/26

NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting

141

Europe, Canada, Japan, US, RoW

GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227

GlaxoSmithKline

Neoplasms

09/28

Zhuang, Wu

ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer

Not yet recruiting

738

RoW

TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Extensive Small Cell Lung Cancer

12/22

NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Recruiting

404

RoW

PM8002, Paclitaxel, Topotecan

Biotheus Inc.

SCLC

01/27

12/28

NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Recruiting

200

RoW

TQ-B3101

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Malignant Tumor

03/21

09/21

STAMP, NCT04933175: Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

Not yet recruiting

RoW

Fluzoparil, Anlotinib

Liu Zhenhua

Extensive Stage Small Cell Lung Cancer

06/22

06/23

NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

Recruiting

RoW

HLX07+HLX10+ Cisplatin+5-FU, HLX07

Shanghai Henlius Biotech

ESCC or Esophageal Adenosquamous Carcinoma

06/24

08/25

NCT04824079: Keynatinib in Treated Patients With NSCLC and Brain Metastases

Recruiting

RoW

Keynatinib, TL007

Medolution Ltd.

Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases

04/25

07/25

NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting

121

RoW

BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, SI-B003

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

11/25

SKB264-II-04, NCT05816252: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer () (MK-2870-003)

Recruiting

498

Europe, RoW

SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT), Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate

Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Non-small Cell Lung Cancer

12/25

10/26

NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting

1/2

133

RoW

KC1036

Beijing Konruns Pharmaceutical Co., Ltd.

Digestive System Tumors

10/25

12/25

NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Recruiting

RoW

JMT101, Afatinib or Osimertinib

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

12/21

06/22

GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting

150

RoW

GQ1005

GeneQuantum Healthcare (Suzhou) Co., Ltd.

HER2 Expressing or Mutated Advanced Malignant Solid Tumors

12/24

07/25

NCT03917043: APG-2449 in Patients With Advanced Solid Tumors

Recruiting

165

RoW

APG-2449, APG-2449 Capsule

Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.

Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma

12/27

01/28

NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Not yet recruiting

N/A

RoW

Osimertinib

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations

06/23

08/23

Lin, Rongbo

FNF-014, NCT03788226: A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

Recruiting

600

RoW

POF, CAPOX/SOX/FOLFOX

Fujian Cancer Hospital

Gastric Cancer Stage III

12/21

12/23

NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting

560

RoW

Irinotecan Hydrochloride Injection, HX008, Placebo

Taizhou Hanzhong biomedical co. LTD

Stomach Cancer

08/23

Active, not recruiting

920

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

ANCHOR, NCT04854668: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, not recruiting

748

RoW

Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin, Capecitabine

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Metastatic Colorectal Cancer

12/24

12/25

NCT04734249: Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Not yet recruiting

Surufatinib(HMPL-012), Chemotherapy(mFOLFOX6/FOLFIRI,FOLFOXIRI)

Fujian Cancer Hospital

Advanced Colorectal Cancer

03/21

12/23

NCT05839470: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Recruiting

RoW

cadonilimab, irinotecan, Oxaliplatin, leucovorin or levoleucovorin, 5-FU

Fujian Cancer Hospital

Colorectal Cancer

03/24

03/25

Not yet recruiting

168

RoW

TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Chemotherapy

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Gastroesophageal Adenocarcinoma

09/26

09/27

NCT06166836: a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Recruiting

1/2

140

RoW

D1553, IN10018（Ifebemtinib）, BI 853520

InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd

Solid Tumor

12/25

12/26

NCT06825494: Clinical Studies for the Treatment of Advanced Solid Tumors

Recruiting

1/2

134

RoW

LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine, LM-108 injection 10mg/kg +penpulimab, LM-108 injection 600mg + penpulimab

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Advanced Solid Tumor

03/26

09/26

NCT04718402: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Terminated

RoW

Mitoxantrone Hydrochloride Liposome, intravenous injection

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Advanced Gastric Carcinoma

05/22

GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting

150

RoW

GQ1005

GeneQuantum Healthcare (Suzhou) Co., Ltd.

HER2 Expressing or Mutated Advanced Malignant Solid Tumors

12/24

07/25

NCT05502393: A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Recruiting

118

RoW

JS107, Toripalimab

Shanghai Junshi Bioscience Co., Ltd.

Advanced Solid Tumors

07/24

12/24

NCT05461768: A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Recruiting

RoW

BL-M07D1

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Breast Cancer, Locally Advanced or Metastatic Solid Tumor

06/25

12/25

NCT06832982: Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

Recruiting

RoW

FS-8002 injection

Shanghai Pushi Medical Science Co. Ltd

Advanced Solid Tumors

09/25

09/26

AWT020-001-I, NCT06839105: A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Not yet recruiting

214

RoW

Taxol, Cisplatin or Carboplatin, Pemetrexed, Oxaliplatin, Capecitabine, Bevacizumab, Renvastinib, AWT020

Shanghai Junshi Bioscience Co., Ltd.

Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

04/28

Recruiting

RoW

TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Colorectal Cancer

03/25

07/25

Chen, Yu

NCT04766307: A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

Recruiting

1100

RoW

Interleukin-2, IL-2

Beijing Chest Hospital

Tuberculosis, Pulmonary

12/21

TB-TRUST, NCT03867136: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

Completed

354

RoW

PZA sensitivity guided ultra-short all Oral Regimen, Standardized Shorter Regimen

Huashan Hospital

Multidrug Resistant Tuberculosis

08/24

NCT06041425: The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE

Completed

RoW

Oxycodone, preemptive analgesia, Sufentanil

The First Affiliated Hospital with Nanjing Medical University

Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Pain, Inflammation

12/23

ERASE, NCT06093191: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Recruiting

364

RoW

Tobramycin Inhalant Product, Inhaled antibiotics, Ciprofloxacin 750 MG, Oral antibiotics, Oral ciprofloxacin placebo, Natural saline inhalation, Inhaled saline

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult, Pseudomonas Aeruginosa Infection

10/25

12/25

MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma

06/22

09/22

NCT05114603: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Recruiting

RoW

HLX208

Shanghai Henlius Biotech

Advanced Melanoma

08/23

08/24

NCT05823246: Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

Recruiting

RoW

QLF31907

Qilu Pharmaceutical Co., Ltd.

Melanoma, Urothelial Carcinoma

10/23

07/24

NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors

Recruiting

115

RoW

VC004

Jiangsu vcare pharmaceutical technology co., LTD

Locally Advanced Solid Tumor, Metastatic Solid Tumor

01/24

06/24

NCT05664139: Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Not yet recruiting

Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel

Fujian Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd., SunWay Biotech Co., LTD.

Malignant Melanoma, Liver Metastases

12/24

12/25

NCT06609369: Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse

Recruiting

114

Experimental health intervention, Varenicline

Yale University, National Institute on Drug Abuse (NIDA)

Tobacco Use, Tobacco Cessation, Insomnia

06/29

NCT06081920: A Study of IBI363 in Subjects With Advanced Melanoma

Recruiting

120

RoW

IBI363

Innovent Biologics (Suzhou) Co. Ltd.

Melanoma

06/25

07/26

NCT04135456: The Optimal Dose of Mannitol for Intraoperative Brain Relaxation During the Operation of Aneurysmal Subarachnoid Hemorrhage

Active, not recruiting

1/2

RoW

Mannitol

Beijing Tiantan Hospital

Aneurysmal Subarachnoid Hemorrhage

11/23

01/24

NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Terminated

1/2

RoW

TJ1133 Injection

TJ Biopharma Co., Ltd.

Advanced Solid Tumor

02/23

PM8002-A001, NCT05918445: PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting

1/2

380

RoW

PM8002

Biotheus Inc.

Malignant Neoplasm

11/25

NCT06214156: A Clinical Study of T3011 in Subjects With Advanced Melanoma

Recruiting

1/2

RoW

T3011

Shanghai Pharmaceuticals Holding Co., Ltd

Advanced Melanoma

09/25

NCT05989958: The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure

Recruiting

1/2

RoW

HepaCure, DPMAS and LPE

Hexaell Biotech Co., Ltd.

Acute on Chronic Hepatic Failure, Liver Failure, Hepatitis

09/26

NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting

1/2

RoW

SPH4336, Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Advanced Solid Tumors

05/25

12/25

KY-0118-ZJKY, NCT06175780: Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting

189

RoW

KY-0118

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Neoplasms, Neoplasms by Histologic Type

12/25

NCT04773951: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Recruiting

156

RoW

JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection

Shanghai Junshi Bioscience Co., Ltd.

Melanoma, Renal Carcinoma, Urothelial Carcinoma

02/24

08/24

NCT04936178: A Study of NB003 in Patients with Advanced Malignancies

Recruiting

258

Europe, US, RoW

NB003 tablets

Ningbo Newbay Technology Development Co., Ltd

Advanced Solid Tumor

07/25

12/25

ADRX-0706-001, NCT06036121: A Study of ADRX-0706 in Select Advanced Solid Tumors

Recruiting

144

US, RoW

ADRX-0706

Adcentrx Therapeutics

Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer

09/25

12/26

DILI-P, NCT02961413: A Prospective Cohort Study on Drug-induced Liver Injury in China（）

Recruiting

N/A

10000

RoW

Drug Induced Liver Disease Study Group

Drug-induced Liver Injury

12/30

TB-TRUSTplus, NCT04717908: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

Completed

N/A

RoW

Bedaquiline, BDQ, Pyrazinamide, PZA, Linezolid, LZD, Cycloserine, Cs, Clofazimine, CFZ

Huashan Hospital

Multidrug Resistant Tuberculosis

06/24

NCT04968028: Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament

Recruiting

N/A

164

RoW

ACAF, Anterior Controllable Antedisplacement and Fusion, Laminoplasty

Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy

07/25

12/26

rTMS, NCT06145932: Repetitive Transcranial Magnetic Stimulation Therapy in Essential Tremor

Recruiting

N/A

RoW

real rTMS, sham rTMS

Second Affiliated Hospital of Soochow University

Essential Tremor

10/26

12/26

GES-aSAH, NCT06346015: Gamma Entrainment Stimulation for Cognitive Dysfunction After aSAH

Not yet recruiting

N/A

Gamma Entrainment Stimulation, Audio-assistied therapy

Beijing Tiantan Hospital, Shanghai Joyingmed Sensory Stimulation Lab

Subarachnoid Hemorrhage, Aneurysmal, Cognitive Dysfunction

03/25

NCT06356506: A Study on Factors of Biochemical Response in Autoimmune Hepatitis

Not yet recruiting

N/A

630

RoW

Beijing Friendship Hospital

Autoimmune Hepatitis

05/34

NCT06760273: Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

Recruiting

N/A

364

RoW

No Intervention: Observational Cohort

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult

12/27

OHAVM, NCT04136860: Long-term Outcomes After Different Management Strategies for High-level Cerebral Arteriovenous Malformation

Recruiting

N/A

1000

RoW

Beijing Tiantan Hospital, Peking University International Hospital

Arteriovenous Malformation of Brain

11/24

12/24

NCT04662918: Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

Recruiting

N/A

3000

Europe, US, RoW

Xingshun Qi

GastroIntestinal Bleeding

12/24

NCT05885828: The PRECISION-T2D Study: Precision Nutrition Study for Type 2 Diabetes

Recruiting

N/A

200

RoW

White bread, Breakfast A, Whole wheat bread, Breakfast B, Plant-based diet, Conventional diabetic diet, Follow-up visit every 1-2 years

Westlake University, Hangzhou Third People's Hospital

Type 2 Diabetes

12/24

12/33

NCT05720299: A Clinical Study to Evaluate the Effects of Akkermansia Muciniphila and Berberine on Prediabetes Among Obese Subjects.

Recruiting

N/A

RoW

Akkermansia muciniphila, Berberine, AKK Placebo, Berberine Placebo

Yu Chen

Prediabetes

02/26

RADAR, NCT06902415: Application of QDSA Platform in Cerebrovascular Diseases

Recruiting

N/A

1000

RoW

QDSA (Quantitative Digital Subtraction Angiography)

Beijing Tiantan Hospital

Cerebrovascular Disease

02/30

12 »

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites